Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Kentaro Yamazaki, M. Nagase, H. Tamagawa, S. Ueda, T. Tamura, K. Murata, T. Eguchi Nakajima, E. Baba, M. Tsuda, T. Moriwaki, T. Esaki, Y. Tsuji, K. Muro, K. Taira, T. Denda, S. Funai, K. Shinozaki, H. Yamashita, N. Sugimoto, T. OkunoT. Nishina, M. Umeki, T. Kurimoto, T. Takayama, A. Tsuji, M. Yoshida, A. Hosokawa, Y. Shibata, K. Suyama, M. Okabe, K. Suzuki, N. Seki, K. Kawakami, M. Sato, K. Fujikawa, T. Hirashima, T. Shimura, K. Taku, T. Otsuji, F. Tamura, E. Shinozaki, K. Nakashima, H. Hara, T. Tsushima, M. Ando, S. Morita, N. Boku, I. Hyodo

Research output: Contribution to journalArticlepeer-review

134 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)'. Together they form a unique fingerprint.

Medicine & Life Sciences